Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side effects...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Ovarian Res
Main Authors: Ni, Jing, Cheng, Xianzhong, Zhou, Rui, Xu, Xia, Guo, Wenwen, Chen, Xiaoxiang
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6882236/
https://ncbi.nlm.nih.gov/pubmed/31775908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-019-0594-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki